Cimzia and Novalgin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cimzia (certolizumab pegol) and Novalgin (metamizole). Common drug interactions include blood pressure increased among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Cimzia and Novalgin. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Cimzia?

Cimzia has active ingredients of certolizumab pegol. It is often used in rheumatoid arthritis. eHealthMe is studying from 106,745 Cimzia users. Check the latest studies of Cimzia.

What is Novalgin?

Novalgin has active ingredients of metamizole. It is often used in pain. eHealthMe is studying from 10,177 Novalgin users. Check the latest studies of Novalgin.



On Jul, 12, 2026

18 people who take Cimzia and Novalgin together, and have interactions are studied.

Cimzia and Novalgin drug interactions.

What are the common drug interactions of Cimzia and Novalgin, by gender? *:

female:

  1. Blood pressure increased
  2. Pneumonia
  3. Application site discolouration
  4. Application site pain
  5. Drug ineffective
  6. Dysphonia (speech disorder attributable to a disorder of phonation)
  7. Headache (pain in head)
  8. Influenza
  9. Abscess (pus)
  10. Arthralgia (joint pain)

male:

  1. Pneumonia
  2. Alveolitis (inflammation in the socket of a tooth)
  3. Neutrophilia
  4. Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)
  5. Respiratory failure (inadequate gas exchange by the respiratory system)
  6. Body temperature increased
  7. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  8. Cough
  9. Fatigue (feeling of tiredness)
  10. Herpes zoster oticus (viral infection of the inner, middle, and external ear caused by varicella-zoster virus (vzv))

What are the common drug interactions of Cimzia and Novalgin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Alveolitis (inflammation in the socket of a tooth)
  2. Body temperature increased
  3. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  4. Cough
  5. Fatigue (feeling of tiredness)
  6. Herpes zoster oticus (viral infection of the inner, middle, and external ear caused by varicella-zoster virus (vzv))
  7. Interstitial lung disease
  8. Lymphocytosis (an increase in the number or proportion of lymphocytes in the blood)
  9. Meningitis viral (viral inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)
  10. Neutrophilia

50-59:

  1. Arthralgia (joint pain)
  2. Chills (felling of cold)
  3. Compartment syndrome (painful condition that occurs when pressure within the muscles builds to dangerous levels)
  4. Erythema (redness of the skin)
  5. Haematoma (collection of blood outside the blood vessels)
  6. Oedema peripheral (superficial swelling)
  7. Pain in extremity
  8. Pyrexia (fever)
  9. Staphylococcal abscess (pus formation due to staphylococcal bacteria)
  10. Wound

60+:

  1. Pneumonia
  2. Blood pressure increased
  3. Chemotherapy
  4. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  5. Dilatation ventricular
  6. Hepatic steatosis (fatty liver disease)
  7. Hepatomegaly (abnormal enlargement of the liver)
  8. Hysterectomy
  9. Liver abscess (pus in liver)
  10. Lymphocele (a collection of lymphatic fluid within the body not bordered by epithelial lining)

What are the existing conditions these people have? *

  1. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 6 people, 33.33%
  2. High Blood Pressure: 5 people, 27.78%
  3. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 22.22%
  4. Osteoporosis (bones weak and more likely to break): 3 people, 16.67%
  5. Gastritis Erosive (a break in the surface layer of the membrane lining the stomach with infection): 2 people, 11.11%
  6. Ankylosing Spondylitis (type of arthritis affecting the spine): 2 people, 11.11%
  7. Body Temperature Increased: 2 people, 11.11%
  8. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 2 people, 11.11%
  9. Diabetes: 2 people, 11.11%
  10. Vitamin B1 Deficiency: 2 people, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Cimzia and Novalgin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cimzia and Novalgin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cimzia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Novalgin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cimzia and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Novalgin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on certolizumab pegol and metamizole (the active ingredients of Cimzia and Novalgin, respectively), and Cimzia and Novalgin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: